Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter B Berger

Showing results (81-90 of 193) with videos related to

Pageof 20
Sort By:
Mayo Clinic Proceedings|March 14, 2007
Relationship between age-related macular degeneration-associated variants of complement factor H and LOC387715 with coronary artery diseaseJose S Pulido, Joseph P McConnell, Ryan J Lennon, et al.
American Heart Journal|March 29, 2008
The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trialPatricia J M Best, Steven R Steinhubl, Peter B Berger, et al.
International Journal of Cardiology|March 10, 2017
Influence of statin therapy at time of stroke onset on functional outcome among patients with atrial fibrillationDarae Ko, Jonathan L Thigpen, James A Otis, et al.
Circulation. Cardiovascular Interventions|May 11, 2016
Patients With Chronic Total Occlusions Undergoing Percutaneous Coronary Interventions: Characteristics, Success, and OutcomesEdward L Hannan, Ye Zhong, Alice K Jacobs, et al.
Annals of Internal Medicine|July 16, 2003
Management of patients undergoing percutaneous coronary revascularizationGlenn N Levine, Morton J Kern, Peter B Berger, et al.
Circulation. Cardiovascular Interventions|October 20, 2011
Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summaryDavid P Faxon, John W Eikelboom, Peter B Berger, et al.
Circulation. Cardiovascular Quality and Outcomes|January 15, 2015
Validity of international classification of disease codes to identify ischemic stroke and intracranial hemorrhage among individuals with associated diagnosis of atrial fibrillationJonathan L Thigpen, Chrisly Dillon, Kristen B Forster, et al.
The Canadian Journal of Cardiology|May 15, 2016
Disparities in the Use of Drug-Eluting Coronary Stents by Race, Ethnicity, Payer, and HospitalEdward L Hannan, Michael J Racz, Gary Walford, et al.
Circulation. Cardiovascular Interventions|December 25, 2009
Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrelJuzar O Lokhandwala, Patricia J M Best, Joseph H Butterfield, et al.
American Heart Journal|April 21, 2009
Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trialMatthew J Price, Peter B Berger, Dominick J Angiolillo, et al.
Pageof 20

Showing results (81-90 of 193) with videos related to

Sort By:
Pageof 20
Mayo Clinic Proceedings|March 14, 2007
Relationship between age-related macular degeneration-associated variants of complement factor H and LOC387715 with coronary artery diseaseJose S Pulido, Joseph P McConnell, Ryan J Lennon, et al.
American Heart Journal|March 29, 2008
The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trialPatricia J M Best, Steven R Steinhubl, Peter B Berger, et al.
International Journal of Cardiology|March 10, 2017
Influence of statin therapy at time of stroke onset on functional outcome among patients with atrial fibrillationDarae Ko, Jonathan L Thigpen, James A Otis, et al.
Circulation. Cardiovascular Interventions|May 11, 2016
Patients With Chronic Total Occlusions Undergoing Percutaneous Coronary Interventions: Characteristics, Success, and OutcomesEdward L Hannan, Ye Zhong, Alice K Jacobs, et al.
Annals of Internal Medicine|July 16, 2003
Management of patients undergoing percutaneous coronary revascularizationGlenn N Levine, Morton J Kern, Peter B Berger, et al.
Circulation. Cardiovascular Interventions|October 20, 2011
Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summaryDavid P Faxon, John W Eikelboom, Peter B Berger, et al.
Circulation. Cardiovascular Quality and Outcomes|January 15, 2015
Validity of international classification of disease codes to identify ischemic stroke and intracranial hemorrhage among individuals with associated diagnosis of atrial fibrillationJonathan L Thigpen, Chrisly Dillon, Kristen B Forster, et al.
The Canadian Journal of Cardiology|May 15, 2016
Disparities in the Use of Drug-Eluting Coronary Stents by Race, Ethnicity, Payer, and HospitalEdward L Hannan, Michael J Racz, Gary Walford, et al.
Circulation. Cardiovascular Interventions|December 25, 2009
Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrelJuzar O Lokhandwala, Patricia J M Best, Joseph H Butterfield, et al.
American Heart Journal|April 21, 2009
Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trialMatthew J Price, Peter B Berger, Dominick J Angiolillo, et al.
Pageof 20